CDNA — CareDx, Inc stock price, charts and financials

QT87CareDx, Inc

CareDx, Inc (NASDAQ: CDNA) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
47.09
-0.76-1.59%
OverviewShort InterestFilings
CDNAQT87CareDx, Inc·NASDAQ
47.09-1.59%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NEOG-0.76%$11.81VCYT+3.48%$46.41PSNL+2.42%$13.52SHC+0.67%$18.11RDNT+3.62%$69.22TWST-1.59%$99.45CSTL+2.60%$31.18BLLN+3.59%$142.25
Snapshot
Index-P/E22.75EPS (ttm)2.07Insider Own8.91%Shs Outstand51.66MPerf Week31.72%
Market Cap2.43BForward P/E36.56EPS next Y1.29Insider Trans-5.80%Shs Float49.32MPerf Month62.04%
Enterprise Value2.07BPEG0.74EPS next Q0.17Inst Own-Short Float12.54%Perf Quarter124.67%
Income112.00MP/S5.31EPS this Y-49.18%Inst Trans-Short Ratio7.33Perf Half Y130.61%
Sales458.00MP/B5.71EPS next Y22.43%ROA20.83%Short Interest6.19MPerf YTD149.95%
Book/sh8.25P/C6.50EPS next 5Y30.79%ROE32.81%52W High49.76 -5.37%Perf Year285.35%
Cash/sh7.24P/FCF26.55EPS past 3/5Y-ROIC25.30%52W Low11.26 318.21%Perf 3Y321.95%
Dividend Est.-EV/EBITDA16.06Sales past 3/5Y5.68% 14.63%Gross Margin49.12%Volatility7.97% 5.80%Perf 5Y-43.60%
Dividend TTM-EV/Sales4.52EPS Y/Y TTM122.58%Oper. Margin24.26%ATR (14)2.48Perf 10Y895.56%
Dividend Ex-Date-Quick Ratio4.51Sales Y/Y TTM37.13%Profit Margin24.23%RSI (14)78.66Recom2.23
Dividend Gr. 3/5Y-Current Ratio4.58EPS Q/Q270.00%SMA2029.65%Beta2.41Target Price51.67
Payout0.00%Debt/Eq0.07Sales Q/Q51.72%SMA5060.26%Rel Volume1.68Prev Close47.85
Employees765LT Debt/Eq0.07EarningsNov 03SMA200121.26%Avg Volume982.68KPrice47.09
IPO DateJul 17, 2014Option/ShortYes / YesEPS/Sales Surpr.59.39% 15.92%Net Debt/EBITDA-2.78Volume1,646,952Change-1.59%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-03-26ReiteratedCraig-HallumBuy$35 → $64
Jul-31-26ReiteratedHC Wainwright & Co.Neutral$25 → $46
Jul-16-26ReiteratedCraig-HallumBuy$26 → $35
Jul-16-26ReiteratedBTIGBuy$28 → $45
Apr-29-26ReiteratedBTIGBuy$26 → $28
Jan-06-26ReiteratedCraig-HallumBuy$40 → $26
Dec-15-25ReiteratedWells FargoEqual Weight$18
Mar-03-25ReiteratedHC Wainwright & Co.Neutral$25
Jan-15-25UpgradeWells FargoUnderweight → Equal Weight
Nov-05-24ReiteratedBTIGBuy$40 → $35
Latest News
Jul-31-26
Jul-31-2606:45PM
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com
05:24PM
Why CareDx Stock Jumped Todayfool.com
Jul-30-26
Jul-30-2609:13PM
CareDx, Inc. (CDNA) Q2 2026 Earnings Call Transcriptseekingalpha.com
07:03PM
CareDx, Inc. 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
06:26PM
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimateszacks.com
06:06PM
CareDx Q2 Earnings Call Highlightsmarketbeat.com
04:01PM
CareDx Announces Second Quarter 2026 Financial Resultsbusinesswire.com
Jul-23-26
Jul-23-2611:01AM
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?zacks.com
Jul-21-26
Jul-21-2603:15AM
Amova Asset Management Americas Inc. Increases Position in CareDx, Inc. $CDNAdefenseworld.net
Jul-20-26
Jul-20-2608:15AM
CareDx's Growth Prospects With Naveris Keep Me Bullishseekingalpha.com
Jul-17-26
Jul-17-2606:20AM
CareDx (CDNA) Moves 35.6% Higher: Will This Strength Last?zacks.com
Jul-16-26
Jul-16-2607:00PM
What's going on in today's sessionChartMill
08:35AM
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026businesswire.com
08:30AM
CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determinationbusinesswire.com
Jul-07-26
Jul-07-2612:26PM
CareDx Completes Naveris Acquisition and Expands Oncology Reachzacks.com
Company

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue45838033428032229619212777
Cost of Goods Sold Incl. D&A10112511010211297634533
Gross Profit2252542241782101991298244
Selling, General and Administrative Excl. Other2482102062011961521037544
Research and Development797172829077493115
Other Operating Expense-3-6-95991000-1
Operating Income111-2141-203-77-30-23-25-16
Interest Expense000000004
Unusual Expense
—————————
Non-Operating Income (Expense)4012131-231-29
Net Income Before Taxes116-2153-190-76-32-20-24-48
Income Taxes-40000-1-1-2-1
Consolidated Net Income112-2153-190-77-31-19-22-47
Net Income From Continuing Operations112-2153-190-77-31-19-22-47
Net Income112-2153-190-77-31-19-22-47
EPS (Recurring)2.15-0.401.00-3.54-1.44-0.59-0.40-0.52-1.31
EPS (Basic, Before Extraordinaries)2.15-0.401.00-3.54-1.44-0.59-0.40-0.52-1.31
EPS (Diluted)2.07-0.400.93-3.54-1.44-0.59-0.40-0.52-1.31
EBITDA129-1-34-85-60-20-8-17-11
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio22.75—23.02——————
Price To Sales Ratio5.242.633.402.311.887.9917.367.1311.75
Gross Margin49.1366.8467.0763.5765.2267.2367.1964.5757.14
Operating Margin24.24-5.5312.28-72.50-23.91-10.14-11.98-19.69-20.78
Net Margin24.45-5.5315.87-67.86-23.91-10.47-9.90-17.32-61.04
Shares Outstanding515353545352464236
Market Capitalization2,4029991,1356486052,3653,333906905
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$53.29$41.50$29.71$17.92$6.13● Close Price0.00M1.37M2.75M4.12M5.50MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Hanna John Walter JRPresident and CEOJul 16 '26Option Exercise8.20118,000967,600771,448Jul 17
Hanna John Walter JRPresident and CEOJul 16 '26Sale37.79118,0004,458,637653,448Jul 17
Valantine HannahDirectorJul 16 '26Option Exercise14.7628,779424,89565,465Jul 17
Valantine HannahDirectorJul 16 '26Sale36.1528,7791,040,24336,686Jul 17
Hanna John Walter JRPresident and CEOJun 29 '26Sale29.2439,9001,166,836661,959Jun 30
Hanna John Walter JRPresident and CEOJun 29 '26Option Exercise8.2039,900327,180701,859Jun 30
Hanna John Walter JRPresident and CEOJun 26 '26Option Exercise8.20100820662,059Jun 30
Hanna John Walter JRPresident and CEOJun 26 '26Sale29.001002,900661,959Jun 30
Hanna John Walter JRPresident and CEOJun 15 '26Option Exercise8.2015,676128,543661,959Jun 30
Hanna John Walter JRPresident and CEOJun 11 '26Option Exercise8.2013,618111,668646,283Jun 30
Hanna John Walter JRPresident and CEOJun 04 '26Option Exercise8.207065,789632,665Jun 30
Hanna John Walter JRPresident and CEOJun 15 '26Sale24.0317,683424,877631,959Jun 17
Valantine HannahDirectorJun 15 '26Sale23.1112,103279,72836,686Jun 16
Hanna John Walter JRPresident and CEOJun 11 '26Sale24.0221,998528,443649,642Jun 15
Hanna John Walter JRPresident and CEOJun 04 '26Sale24.004,835116,045671,640Jun 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.